Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 250.80K | 324.10K | 414.90K | 406.00K | 1.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.80K | 324.10K | 414.90K | 406.00K | 1.69M |
| Cost of Revenue | 176.60K | 231.30K | 235.60K | 174.80K | 174.80K |
| Gross Profit | 74.30K | 92.90K | 179.40K | 231.20K | 231.20K |
| SG&A Expenses | 1.08M | 1.27M | 1.00M | 1.04M | 1.04M |
| Depreciation & Amortization | 34.10K | 33.70K | 33.20K | 32.60K | 32.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29M | 1.54M | 1.27M | 1.24M | 2.28M |
| Operating Income | -1.04M | -1.21M | -856.20K | -838.00K | -593.90K |
| Income Before Tax | 8.18M | -1.01M | -1.77M | -1.93M | -1.93M |
| Income Tax Expenses | 1.20M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.98 | -1.01 | -1.77 | -1.93 | -1.93 |
| Earnings from Discontinued Operations | 925.30K | 149.30K | 405.30K | 581.40K | 581.40K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -30.10K | -112.40K | -161.70K | -161.70K |
| Net Income | 7.90M | -895.80K | -1.47M | -1.51M | -5.90M |
| EBIT | -1.04M | -1.21M | -856.20K | -838.00K | -593.90K |
| EBITDA | -1.01M | -1.18M | -823.10K | -805.50K | -557.60K |
| EPS Basic | 0.05 | -0.01 | -0.01 | -0.01 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.05 | -0.01 | -0.01 | -0.01 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |